Compare · QTRX vs RVTY
QTRX vs RVTY
Side-by-side comparison of Quanterix Corporation (QTRX) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both QTRX and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $13.93B, about 105.6x QTRX ($131.9M).
- QTRX has been more active in the news (13 items in the past 4 weeks vs 6 for RVTY).
- RVTY has more recent analyst coverage (20 ratings vs 13 for QTRX).
- Company
- Quanterix Corporation
- Revvity Inc.
- Price
- -
- -
- Market cap
- $131.9M
- $13.93B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 13
- 6
- Recent ratings
- 13
- 20
Quanterix Corporation
Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Latest QTRX
- Director Elliott Jeffrey Thomas converted options into 3,955 shares, increasing direct ownership by 35% to 15,345 units (SEC Form 4)
- SEC Form 3 filed by new insider Gute James Edward Jr.
- Director Donnelly William P converted options into 2,802 shares, increasing direct ownership by 2% to 162,401 units (SEC Form 4)
- Chief Technology Officer Miller Michael Francis converted options into 1,558 shares and covered exercise/tax liability with 467 shares, increasing direct ownership by 3% to 37,250 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Quanterix Corporation
- SEC Form 10-Q filed by Quanterix Corporation
- Quanterix Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Quanterix Names Jim Gute Chief Commercial Officer
- Quanterix Releases Financial Results for the Second Quarter of 2026
- SEC Form SCHEDULE 13G filed by Quanterix Corporation
Latest RVTY
- Director Michas Alexis P gifted 285 shares (SEC Form 4)
- Officer Goldberg Joel S gifted 27,785 shares and received a gift of 27,785 shares, decreasing direct ownership by 67% to 13,729 units (SEC Form 4)
- Officer Singh Prahlad R. gifted 67,286 shares and received a gift of 67,286 shares, decreasing direct ownership by 59% to 46,026 units (SEC Form 4)
- SEC Form 10-Q filed by Revvity Inc.
- Revvity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Revvity Announces Financial Results for the Second Quarter of 2026
- Revvity Board Declares Quarterly Dividend
- Vice President and CAO Gonzales Anita sold $9,306 worth of shares (85 units at $109.48) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 7,201 units (SEC Form 4)
- Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure
- Revvity to Hold Earnings Call on Tuesday, August 4, 2026